ClinicalTrials.gg
RecruitingNCT06421987Updated Sep 1, 2026

Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors

An observational study in Hodgkin Lymphoma, Adult, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by St. Jude Children's Research Hospital · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital — 6 open to participants now, 13 under way, none of them phase 3. Hodgkin Disease · St. Jude Children's Research Hospital.

Started
2024
with 1 other
Observational
9 of 27
3 open now
Primary completion
2026-12
later than 5 of 12 live
Registered
24th of 27
by date

Among the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, this one is one of 2 that started in 2024, is one of 9 observational ones, reaches primary completion later than 5 of the 12 other live ones, and was the 24th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

6 of the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

SURVIVORS

Study participants are being asked to take part in this research study called HODNIRS because the participant is a survivor of Hodgkin Lymphoma (HL) treated with chest radiation and bleomycin at St. Jude Children's Research Hospital. The study is being done to help investigators understand the link between long term effects of chest radiation and bleomycin for HL and brain function in survivors.

Primary Objective To evaluate dynamic changes in CBF and oxygenation during exercise with Near Infrared Spectroscopy (NIRS) in HL survivors and non-cancer controls matched for age, sex, race, and ethnicity. .

Secondary Objectives To examine the degree of CO2 clearance (DLCO/ETCO2) during rest and exercise in Hodgkin Lymphoma (HL) survivors compared to non-cancer controls matched for age, sex, race, and ethnicity.

CONTROLS

Volunteers are being asked to take part in this research study because they are non-first degree relative or friend of someone who received treatment for a childhood cancer or similar illness at St. Jude Children's Research Hospital or are an employee/affiliate of St. Jude Children's Research Hospital and have agreed to be a St. Jude Life Cohort Study (SJLIFE) community control.

Read the detailed description

NIRS is a portable, non-invasive, brain imaging device that uses low levels of non-ionizing light to record variations in blood flow in the brain. The NIRS is wearable and can read blood flow to the brain during physical activity.

03

Conditions studied

  • Hodgkin Lymphoma, Adult

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All participants who meet eligibility criteria and consent to enrollment on the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

HL Survivors

  • Completed bleomycin and/or thoracic radiation therapy for HL at SJCRH.
  • \<21-years old at diagnosis; currently ≥18-years of age and ≥2-years post therapy.
  • SJLIFE or ACT/SJLIFE participants
  • English language proficiency.

Community Controls

  • SJLIFE control.
  • ≥18-years of age at the time of enrollment with age sampling to broadly match the HL survivors.

Exclusion criteria

Exclusion Criteria:

HL Survivors

  • History of cranial or total-body irradiation therapy.
  • History of intrathecal or high dose intravenous antimetabolite therapy.
  • History of head injury or diagnosis of a genetic disorder associated with cognitive impairment.
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • SURVIVOR

    A survivor of Hodgkin Lymphoma (HL) treated with chest radiation and bleomycin at St. Jude Children's Research Hospital. and Control: Voluntarily taking part in this study because you are a relative, friend or employee of St. Jude Children's Research Hospital.

    Device: Near Infrared Spectroscopy (NIRS)

Interventions

  • DeviceNear Infrared Spectroscopy (NIRS)

    NIRS is a portable, non-invasive, brain imaging device.

06

What researchers measure

Primary outcomes

  1. Near-Infrared Spectroscopy (NIRS)

    a non-invasive imaging technology that is used to measure regional or global cerebral tissue oxygenation and cerebral blood flow (CBF) during exercise. NIRS takes advantage of the fact that oxygenated blood and de-oxygenated blood absorb light differently. By measuring the reflected light from blood, the concentration of both oxygenated hemoglobin (HbO2) and deoxygenated hemoglobin (HbdO2) using the modified Beer-Lambert Law can be calculated.

    Time frame: Baseline

Secondary outcomes

  1. Cardiopulmonary Exercise Testing (CPX)

    Cardiopulmonary Exercise Testing (CPX) will be performed with the goal of maximal exertion. Participants are monitored with 12-lead electrocardiogram (ECG) and serial blood pressure measurements during and after exercise, and during recovery. Study participants whose physical performance does not permit walking safely on the treadmill, will perform CPX on a bicycle or upper extremity ergometer using a comparable testing protocol. Oxygen consumption during CPX- Oxygen will be measured at baseline and continuously during CPX. Total minute ventilation (respiratory rate X tidal volume; l/min), and ventilatory reserve (l/min) will be used to assess the ability of the pulmonary system to respond to exercise.

    Time frame: Baseline

  2. Pulmonary Function Testing

    As part of the St. Jude Life (SJLIFE) study visit, participants will complete PFT's performed in a single laboratory according to the American Thoracic Society Task Force Guidelines. Pulmonary Function Tests (PFTs) will include: 1. Forced vital capacity (FVC) - measured in liters 2. Forced expiratory volume in 1 second (FEV1) - measured in liters/per second 3. FEV1/FVC ratio - measurement will be a percent. 4. DLCO capacity of lung to transfer carbon monoxide - measured in mL/min/mm Hg. These measurements will be compared with those predicted for the participant's age, race, sex, and height.

    Time frame: Baseline

  3. Neurocognitive Outcomes

    \- As part of the SJLIFE study visit, participants will complete neurocognitive testing (Wechsler Abbreviated Scale of Intelligence; Connors Continuous Performance; California Verbal Learning; Coding Digital Symbol; Grooved Pegboard; Trail Making; Verbal Fluence; Visual Selective; Digital Span; and Rey Complex). All tests are converted to z-scores (1.0 z-score is 1 standard deviation lower than the mean).

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 59 non-industry observational studies under Hodgkin Disease, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 149. This study's planned 31 months is below that.

Counting every sponsor, half of 66 studies reached it within 61 months; a quarter within 34 and three quarters within 149.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2024
First posted
May 20, 2024
StartActual
May 6, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06421987
Responsible party
Sponsor
First posted
May 20, 2024
Start date
May 6, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Nicholas Phillips, PhD
Contact
referralinfo@stjude.org
888-226-4343
Nicholas Phillips, PhD
principal investigator · St. Jude

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion